Azione EPRX EUPRAXIA PHARMACEUTICALS INC.
Aggiungi a un elenco
Solo clienti o iscritti possono usare questa funzione
AccediRegistrati

Altre lingue Eupraxia Pharmaceuticals Inc.

Azioni

EPRX

CA29842P1053

Mercato chiuso - Toronto S.E.
Altri mercati azionari
 22:00:00 15/07/2024 		Variaz. 5gg Var. 1 gen.
3,68 CAD -0,54% Grafico intraday di Eupraxia Pharmaceuticals Inc. +5,75% -31,47%
22/05 Aggiornamento settoriale: i titoli del settore sanitario sono in ribasso nel premercato di mercoledì MT
22/05 Aggiornamento settoriale: Assistenza sanitaria MT

Altre lingue

Ricerca
Vedi i risultati
Sblocca tutte le notizie: sii il primo a essere informato e reagisci prima dei mercati!
Registrazione 100% gratuita
Eupraxia Pharmaceuticals Inc. Brief: Says CEO Dr. James Helliwell to Participate in Webinar Event, 'Exploring the Rapid Rise of Osteoarthritis' on July 9, 2024
Eupraxia Pharmaceuticals' CEO Dr. James Helliwell to Participate in Webinar Event, "Exploring the Rapid Rise of Osteoarthritis" on July 9, 2024
Eupraxia Pharmaceuticals Announces Voting Results from Annual General and Special Meeting of Shareholders
Eupraxia Pharmaceuticals Inc. Brief: Says To Present Data from the Phase 2 SPRINGBOARD Study in Osteoarthritis of the Knee at EULAR European Congress of Rheumatology 2024
Eupraxia Pharmaceuticals Expanding RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis
Eupraxia Pharmaceuticals Inc. Brief: Announcing Expansion of RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis
Eupraxia Pharmaceuticals Announces Expansion of RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis
Sector Update: Health Care Stocks Lower Premarket Wednesday
Sector Update: Health Care
Eupraxia Pharmaceuticals to Host Virtual KOL Event on EP-104GI Clinical Development Program for Eosinophilic Esophagitis ("EoE") on May 29, 2024
Eupraxia Pharmaceuticals Announces Data from the Phase 1b/2a RESOLVE Clinical Trial
Eupraxia Pharmaceuticals Reports Positive Data From Eosinophilic Esophagitis Treatment Study -- Shares Rise After Hours
Update On Eupraxia Pharmaceuticals: Now Up 40% In US After Hours, Was Up As Much As 70%
Eupraxia Pharmaceuticals Up 70% In US After Hours As Announces New "Positive" Data from RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis
Eupraxia Pharmaceuticals Inc. Brief: Announcing New "Positive" Data from RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis
Eupraxia Pharmaceuticals Inc. Announces New Positive Data from Resolve Phase 1B/2A Trial of Ep-104Gi for Treatment of Eosinophilic Esophagitis
Eupraxia Pharmaceuticals Announces New Positive Data from RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis
Eupraxia Pharmaceuticals Inc. Brief: Says To Present Initial Results from Ongoing Phase 1b Study of EP-104GI for Treatment of Eosinophilic Esophagitis at Upcoming Digestive Disease Week Annual Meeting 2024
Eupraxia Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update
Eupraxia Pharmaceuticals Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
Non ci sono risultati per questa ricerca
Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Filtri

Cerca

Data di pubblicazione

Da

A

  1. Borsa valori
  2. Azioni
  3. Azione EPRX
  4. Notizie Eupraxia Pharmaceuticals Inc.
  5. Altre lingue